ArticleEJNMMI radiopharmacy and chemistry2017
Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics.
Article in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026Review
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Tetrazine-Inorganic chemistry frontiers · 2026Article
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.EJNMMI radiopharmacy and chemistry · 2025Article
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Preclinical investigation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.Nuclear medicine and molecular imaging · 2025Review
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
- Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Terbium-149 production: a focus on yield and quality improvement towards preclinical application.Scientific reports · 2024Article
- Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Terbium sisters: current development status and upscaling opportunities.Frontiers in nuclear medicine · 2024Review
- Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.